# US 2009/0291124 A1 · Functional Nano-Layered Hemostatic Material/Device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0291124 A1
- Document ID: US20090291124A1
- Status: Published application
- Kind: A1
- Application number: 12/125,096
- Filed: 2008-05-22
- Published: 2009-11-26
- Earliest claimed: 2008-05-22
- Assignees: Honeywell International Inc.
- Inventors: Robert L. Bedard
- Web page: https://patentgrep.com/patent/US20090291124A1

## CPC

- A61L 15/18: containing inorganic materials
- A61L 15/44: Medicaments
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61L 2300/10: containing or releasing inorganic materials
- A61L 2300/418: Agents promoting blood coagulation, blood-clotting agents, embolising agents
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61L 2300/606: Coatings
- A61L 2400/04: Materials for stopping bleeding
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- Y10T 442/20: Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
- Y10T 442/2525: Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention utilizes a nano-coating of an oxide such as silica, a silicate or another effective oxide on a surface to accelerate blood clotting in mammalian animals. The hemostatic layer has a thickness that is effective for the hemostasis, yet can be made thin enough to result in a resorbable film which can either be applied to a biocompatible or resorbable device that can be used in surgical applications as well as in topical applications such as trauma.

## Claims

### Claim 1

A hemostatic article comprising a layer of a hemostatically effective coating on a surface or a material wherein said coating porous carrier and an adsorbent composition wherein said hemostatically effective coating comprises an oxide selected from the group consisting of SiO2, silicate, aluminosilicate, GeO2, silicogermanate, germanate, AlPO4, metal or main group aluminophosphate, and Fe2O3 and mixtures thereof.

### Claim 2 (depends on 1)

The hemostatic article of claim 1 wherein said layer is between 5 and 750 nm thick.

### Claim 3 (depends on 1)

The hemostatic article of claim 1 wherein said layer is between 10 and 500 nm thick.

### Claim 4 (depends on 1)

The hemostatic article of claim 1 wherein said layer is between 10 and 250 nm thick.

### Claim 5 (depends on 4)

The hemostatic article of claim 4 wherein said layer is formed by chemical vapor deposition, atomic layer deposition, plasma-enhanced deposition, electrophoretic deposition, a sol gel process or a spray process.

### Claim 6 (depends on 1)

The hemostatic article of claim 1 wherein said hemostatically effective coating is on a surface selected from the group consisting of powders, substrate surfaces, fibers, nonwoven fabrics, polymers, granules or devices.

### Claim 7 (depends on 6)

The hemostatic article of claim 6 wherein said fibers are selected from the group consisting of cellulose, aramid, acrylic, polyester, polyolefin, chemically modified cellulose fibers and liquid crystal polymers.

### Claim 8 (depends on 1)

The hemostatic article of claim 1 wherein the hemostatic article is a woven or non-woven fibrous article.

### Claim 9 (depends on 1)

The hemostatic article of claim 1 wherein said hemostatic article is in a configuration that is selected from the group consisting of a bandage, dressing, gauze, web, film, tape, or patch.

### Claim 10 (depends on 1)

The hemostatic article of claim 1 further comprising an agent selected from the group consisting of analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors.

### Claim 11

A method of treating a wound in a mammalian animal comprising placing on said wound a hemostatic article comprising a layer of a hemostatically effective coating on a substrate wherein said hemostatically effective coating comprises an oxide selected from the group consisting of SiO2, GeO2, AlPO4 and Fe2O3 and mixtures thereof.

### Claim 12 (depends on 11)

The method of claim 11 wherein said layer is between 5 and 750 nm thick.

### Claim 13 (depends on 11)

The method of claim 11 wherein said layer is between 10 and 500 nm thick.

### Claim 14 (depends on 11)

The method of claim 11 wherein said layer is between 10 and 250 nm thick.

### Claim 15 (depends on 11)

The method of claim 11 wherein the wound is selected from the group consisting of an arterial puncture wound, a venous puncture wound, arterial laceration wound, and a venous laceration wound.

### Claim 16 (depends on 11)

The method of claim 11 wherein the wound is at least one site that is bleeding during a surgical procedure.

### Claim 17 (depends on 11)

The method of claim 11 wherein the porous carrier is selected from the group consisting of non-woven fibrous articles, puff, sponges and mixtures thereof.

### Claim 18 (depends on 11)

The method of claim 11 wherein the porous carrier is a non-woven fibrous article and said fiber is selected from the group consisting of aramids, acrylics, polyester, cellulose, chemically modified cellulose fibers, polyolefms and mixtures thereof.

### Claim 19 (depends on 11)

The method of claim 11 wherein said hemostatically effective coating leaches off the substrate after a period from about two hours to about four weeks.

### Claim 20 (depends on 11)

The method of claim 11 wherein said hemostatic article is in a configuration that is selected from the group consisting of a bandage, dressing, gauze, web, film, tape, or patch.

### Claim 21 (depends on 11)

The method of claim 11 wherein said hemostatic article further comprises an agent selected from the group consisting of analgesics, steroids, antihistamines, anesthetics, bactericides, disinfectants, fungicides, vasoconstrictors, hemostatics, chemotherapeutic drugs, antibiotics, keratolytics, cauterizing agents, antiviral drugs, epidermal growth factor, fibroblast growth factors, transforming growth factors, glycoproteins, fibrinogen, fibrin, humectants, preservatives, lymphokines, cytokines, odor controlling materials, vitamins, and clotting factors.
